Pierre Zachée

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 851 citations

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Lucien Noens, Marie-Anne van Lierde, R. De Bock et al. · Blood · 2009 · 606 citations · Full text

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier et al. · New England Journal of Medicine · 2018 · 357 citations · Full text

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · The Lancet Haematology · 2017 · 316 citations · Full text

Hematological Malignancy, Antifibrotic Therapy, Oncology +7

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee et al. · The Lancet Infectious Diseases · 2019 · 242 citations

Vaccination, Vaccine Safety, Vaccinology +11